RDHL — RedHill Biopharma Ltd.
$0.38
$-0.01 (-1.60%)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.
Market Cap
$3.33M
Forward P/E
12.5x
52-Week Range
N/A
RDHL Price History
Revenue vs. Net Income
$61.8M
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$29.4M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-96.5%
ROCE · FY2022 (approx.)
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.8x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.3%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
61.6K
Diluted shares · FY2022
Only one year of share data is available, so no change can be shown yet.
